ILCA 2024丨Dr. Stephen L. Chan Shares EMERALD-1 Post-Hoc Analysis on Safety and Efficacy Across Different Treatment Phases and Liver Function Levels

ILCA 2024丨Dr. Stephen L. Chan Shares EMERALD-1 Post-Hoc Analysis on Safety and Efficacy Across Different Treatment Phases and Liver Function Levels

The Phase III EMERALD-1 study has shown that for patients with unresectable intermediate to advanced hepatocellular carcinoma (HCC), the combination of durvalumab, bevacizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival (PFS) compared to TACE alone. At the 2024 International Liver Cancer Association (ILCA) conference, Dr. Stephen L. Chan from the Faculty of Medicine at The Chinese University of Hong Kong presented a safety and efficacy analysis from the EMERALD-1 study, considering treatment timing and baseline liver function. In an interview with Oncology Frontier , he shared the latest insights from this analysis.
ESMO 2024丨Docetaxel Remains Standard Therapy for PD-(L)1 Resistant Advanced NSCLC Patients

ESMO 2024丨Docetaxel Remains Standard Therapy for PD-(L)1 Resistant Advanced NSCLC Patients

Anti-PD-(L)1 therapies have been approved for treating advanced non-small cell lung cancer (NSCLC). However, due to limited options, most patients experience disease progression while on anti-PD-(L)1 therapy. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, Dr. Pascale Tomasini from the Multidisciplinary Oncology and Therapeutic Innovations department in Marseille, France, presented findings from the PIONeeR trial—a Phase Ib/IIa study targeting specific resistance pathways in PD-(L)1-resistant advanced NSCLC patients. Oncology Frontier interviewed Dr. Pascale Tomasini on the trial’s main findings, the current treatment strategies for advanced NSCLC patients resistant to PD-(L)1 inhibitors, and future directions.
Dr. Yong Song: Balancing Risks and Benefits of Radiotherapy and Immunotherapy for Optimal Clinical Outcomes

Dr. Yong Song: Balancing Risks and Benefits of Radiotherapy and Immunotherapy for Optimal Clinical Outcomes

Recently, the "Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)" was published, co-authored by Academician Jinming Yu of Shandong Cancer Hospital, Professor Ying Cheng of Jilin Cancer Hospital, and Professor Liangan Chen of the Chinese People’s Liberation Army General Hospital. This publication marks a new level of scientific standardization in the multidisciplinary management of radiotherapy and immunotherapy.Oncology Frontier invited Dr. Yong Song from the Department of Respiratory Medicine, Jinling Hospital, Nanjing University Medical School, one of the core reviewers of the consensus expert group, to share his insights on the consensus guidelines for managing adverse reactions from a respiratory perspective.
ESMO 2024丨Dr. Dingwei Ye’s Team Showcases Chinese Expertise and Innovation in Urologic Oncology on the International Stage

ESMO 2024丨Dr. Dingwei Ye’s Team Showcases Chinese Expertise and Innovation in Urologic Oncology on the International Stage

The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As an annual highlight in the oncology field, ESMO attracts thousands of leading oncologists from around the world, providing a rich platform for global academic exchange. This year, multiple studies from Dr. Dingwei Ye’s team at Fudan University Shanghai Cancer Center were selected for presentation at ESMO. Among them, Professor Ye led the study on "BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)," which received significant attention and discussions, showcasing Chinese expertise and innovation in urologic oncology on a global scale. Urology Frontier had the pleasure of inviting Professor Ye to share his insights on these landmark studies.
Professor Eolia Brissot: The Deepening and Expansion of Blinatumomab in Non-Chemotherapy Strategies for Acute Lymphoblastic Leukemia

Professor Eolia Brissot: The Deepening and Expansion of Blinatumomab in Non-Chemotherapy Strategies for Acute Lymphoblastic Leukemia

The 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association attracted hundreds of domestic and international authoritative experts and scholars in the field of hematology to gather together. During the conference, "Hematology Frontier" specially invited Professor Eolia Brissot from Hôpital Saint-Antoine in Paris to share the latest explorations of non-chemotherapy strategies in the treatment of acute lymphoblastic leukemia.
Treatment Options for MET-Amplified EGFR-Mutated NSCLC Following Third-Generation TKI Resistance

Treatment Options for MET-Amplified EGFR-Mutated NSCLC Following Third-Generation TKI Resistance

For patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), dual inhibition of EGFR and MET may be the most effective strategy after disease progression on osimertinib, particularly for patients with MET gene amplification (METamp). Dr. Benjamin Besse, Dr. Lodovica Zullo, and Dr. Jordi Remon from the Gustave Roussy Institute analyze therapeutic strategies for METamp-driven resistance following osimertinib treatment in this article.
Significant Clinical Research at the 2024 International Liver Cancer Association (ILCA) Annual Conference!

Significant Clinical Research at the 2024 International Liver Cancer Association (ILCA) Annual Conference!

From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference featured the latest research findings from scholars in the global liver cancer field. This article specially compiled the significant clinical research in the field of liver cancer treatment presented at this ILCA conference for the exchange and learning of peers. Our special correspondent from "Oncology Frontier" attended the conference on-site for in-depth coverage, and more exciting content was expected to be shared!
Dr. Christian Chabannon: The Era of Personalized Immunotherapy from a European Perspective

Dr. Christian Chabannon: The Era of Personalized Immunotherapy from a European Perspective

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, China, attracting hundreds of top experts and scholars in the field of hematology from both China and abroad. During the conference, "Hematology Frontier" specially invited Dr. Christian Chabannon from the Paoli-Calmettes Institute in Marseille, France, to discuss the strategies of personalized immunotherapy from a European perspective.
Advancing T-Cell Lymphoma Care: Dr. Owen O’Connor and Dr. Zhengzi Qian Discuss Emerging Therapies

Advancing T-Cell Lymphoma Care: Dr. Owen O’Connor and Dr. Zhengzi Qian Discuss Emerging Therapies

In a recent discussion, Dr. Owen O’Connor and Dr. Zhengzi Qian addressed the complexities of peripheral T-cell lymphoma (PTCL) and shared insights on new therapeutic strategies. They highlighted the diversity of PTCL subtypes and the promising role of novel drugs, such as PI3K inhibitors and EZH2 inhibitors, in improving outcomes. The conversation also emphasized the importance of early combination therapies over traditional chemotherapy and the future potential of chemotherapy-free regimens.
WCLC 2024丨Revolutionary Leap in Lung Cancer: NeoCOAST-2 Unveils Groundbreaking Therapies

WCLC 2024丨Revolutionary Leap in Lung Cancer: NeoCOAST-2 Unveils Groundbreaking Therapies

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently in full swing in San Diego, USA.  Oncology Frontier invited domestic lung cancer experts to analyze key research data from the conference. This article presents Dr. Shengxiang Ren's review of the NeoCOAST-2 study results (Abstract PL02.07) from Shanghai Pulmonary Hospital.